Pfizer and BioNTech Europe GmbH have entered an agreement with Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ COVID-19 vaccine, with an option for an additional 30 million doses. The initial agreement provided 30 million doses of the vaccine to Turkey. This second supply agreement brings the total number of doses to be supplied up to 120 million, all of which will be delivered in 2021.
 
“Our goal is to deliver as many doses of our COVID-19 vaccine as possible to people around the world to help end this pandemic, reduce COVID-19-related hospitalisations and return to a normal life. We are grateful to be able to make an important contribution to Turkey’s vaccination efforts and for the trust placed in us,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.
 
The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the EU, and the holder of emergency use authorizations or equivalent in the U.S. (jointly with Pfizer), UK, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.